Setting a Strategy for Partnering Success
Ipsen is a mid-size pharma company that punches well above its weight. Fresh off its acquisition of Albireo and with more deals on the horizon for 2023, Ipsen is preparing for another successful year of biopharma partnering – but what is their strategy, how do they make the deals happen, and what are the tools they use to get it done?
Philippe Lopes-Fernandes, Executive Vice President and Chief Business Officer of Ipsen, joins Inpart CEO Gilles Toulemonde to explore how he structured his partnering team, where their therapeutic focus lies, how innovative biotechs and academic labs can get on the Ipsen radar, and how to make the most out your presence at partnering meetings.
- Ipsen’s dealmaking strategy and the advantages of partnering with a mid-sized firm
- Tactics and best practices to ensure successful engagement with pharma partners
- How digital tools like Inpart support partnering excellence from sourcing to execution and reputation